David R Corey

USPTO Granted Patents = 20 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 406(Granted Patents)

Company Filing History:

19 out of 5,444

University of Texas System

patents

4 out of 270

Ionis Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840690 - Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat (2023-12-12),

2. 11795457 - Compositions and methods for treatment of Friedreich's Ataxia (2023-10-24),

3. 11512312 - Treatment of Fuchs' endothelial corneal dystrophy (2022-11-29),

4. 11459564 - Modulation of frataxin expression (2022-10-04),

5. 11260073 - Compounds and methods for modulating C90RF72 (2022-03-01),

6. 10538762 - Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat (2020-01-21),

7. 10435430 - Methods and compounds useful in conditions related to repeat expansion (2019-10-08),

8. 9976138 - Methods and compounds useful in conditions related to repeat expansion (2018-05-22),

9. 9574191 - Selective inhibition of polyglutamine protein expression (2017-02-21),

10. 9340785 - Selective inhibition of polyglutamine protein expression (2016-05-17),

11. 8999943 - Antigene oligomers inhibit transcription (2015-04-07),

12. 8901095 - Selective inhibition of polyglutamine protein expression (2014-12-02),

13. 8815586 - Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions (2014-08-26),

14. 8324181 - Modulation of gene expression by oligomers targeted to chromosomal DNA (2012-12-04),

15. 8222221 - Modulation of gene expression through endogenous small RNA targeting of gene promoters (2012-07-17),

Title: Innovator Spotlight: David R. Corey

Introduction

David R. Corey is a distinguished inventor located in Dallas, TX, recognized for his impactful contributions in the field of molecular biology. With an impressive portfolio of 20 patents, his innovative work primarily focuses on therapeutic interventions for various genetic disorders.

Latest Patents

Among his most significant recent patents is the development of "Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat." This invention addresses the urgent need for treatments in patients carrying expanded intronic GGGGCC regions, particularly those at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Additionally, he has pioneered compositions and methods for the treatment of Friedreich's Ataxia, which includes compounds aimed at both therapeutic and investigative applications for this debilitating condition.

Career Highlights

Throughout his career, David Corey has made substantial strides in research and innovation. He has been affiliated with the University of Texas System, where he has collaborated on numerous projects, furthering advancements in scientific understanding and therapeutic options. His role in shaping the direction of research in genetic therapies has marked him as a key figure in the field.

Collaborations

David has collaborated with notable scientists such as Jiaxin Hu and Thazha P. Prakash, reflecting his commitment to teamwork and interdisciplinary research. These partnerships have resulted in groundbreaking findings and have amplified the reach and impact of his inventions across the scientific community.

Conclusion

David R. Corey continues to be a leading force in the realm of genetic research and therapeutics. His innovative patents not only aim to address pressing medical challenges but also inspire future research in molecular medicine. As the landscape of genetic disorders evolves, the contributions of inventors like David signify the importance of innovation in improving lives and transforming healthcare.

This text is generated by artificial intelligence and may not be accurate.